CM101 stimulates cutaneous wound healing through an anti-angiogenic mechanism.
CM101, an anti-pathoangiogenic polysaccharide derived from group B streptococcus, has been shown to inhibit inflammatory angiogenesis and accelerate wound healing in a mouse model and minimize scarring/gliosis following spinal cord injury. To evaluate the in vivo effects of CM101 on cutaneous wound healing in the pig, intravenously delivered CM101 or placebo vehicle was given 1 h after cutaneous wounding and again at 72 h after injury. Tissues from partial-thickness and full-thickness excisions were collected at days 4 and 7 after wounding and evaluated for a variety of standard healing parameters. Both types of CM101-treated wounds showed significantly less evidence of inflammatory angiogenesis when assessed by macroscopic photography of the wound surface, qualitative histological observations, laser doppler perfusion imaging, and quantitative morphometric analysis of microvessel area from endothelium selectively immunostained for factor VIII. Resurfacing was accelerated in partial-thickness and full-thickness excisions that received two doses of CM101 as compared to the placebo-treated excisional wounds. Neodermal thickness was increased in CM101-treated wounds at day 4 and was slightly reduced in comparison with placebo by day 7. New collagen accumulation appeared to be unaffected by the CM101 treatment. Immunohistochemical staining using a polyclonal antisera directed against the anti-pathoangiogenic CM101 target protein HP59 on day 7 indicated a strong immunoreactivity on the microvessels present in the control wounds but not in wounds of the CM101-treated animals. In summary, the immunolocalization HP59 in the microvessels of the cutaneous wound bed in control but not in CM101 treated wounds suggests that CM101 inhibits the pathologic inflammatory angiogenesis accompanying the normal granulation processes. The net biological effect of inhibited inflammatory pathoangiogenesis is a diminished, suggested and purely physiologic, microvascular bed which translates into an enhanced rate of epithelial resurfacing and therefore an overall accelerated rate of wound repair.
Nanney
L B
LB
Department of Plastic Surgery, Department of Cell Biology, Vanderbilt School of Medicine, Nashville, Tennessee, USA. lillian.nanney@mcmail.vanderbilt.edu
Wamil
B D
BD
Whitsitt
J
J
Cardwell
N L
NL
Davidson
J M
JM
Yan
H P
HP
Hellerqvist
C G
CG
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D006097:Granulation Tissue / Q000187:drug effects / Q000473:pathology; D007249:Inflammation / Q000517:prevention & control; D008562:Membrane Glycoproteins; D008565:Membrane Proteins / Q000378:metabolism; D051379:Mice; D008833:Microcirculation / Q000187:drug effects / Q000254:growth & development; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D027361:Organic Anion Transporters; D011135:Polysaccharides, Bacterial / Q000494:pharmacology*; D012867:Skin / Q000098:blood supply / Q000187:drug effects* / Q000293:injuries*; D012879:Skin Physiological Phenomena; D013552:Swine; D027981:Symporters; D014945:Wound Healing / Q000187:drug effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D008562:Membrane Glycoproteins; D008565:Membrane Proteins; D027361:Organic Anion Transporters; D011135:Polysaccharides, Bacterial; D027981:Symporters; C421224:sialic acid transport proteins; C032263:streptococcal polysaccharide type III group B